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Additional Keyphrases: anticonvulsant drugs apoenzyme reactivation immunoassay system reflectance photometry monitoringtherapy Carbamazepine (CBZ) is one of the major drugs used in the treatment of epilepsy. Originally introduced for treating trigeminal neuralgia (1, 2), in the last 10 years it has become one of the anticonvulsants most commonly used for controlling secondarily generalized tonic-clonic seizures, as well as mixed and partial seizures with complex symptomatology (3, 4). In humans, CBZ is metabolized mninly to carbamazepine-10,11-epoxide (CBZ-E), which also has anticonvulsant properties (5-7).Because about 70-80% of the drug is bound to plasma proteins, interindividual variations of its free fraction can lead to marked differences in the drug's therapeutic effect (5,8). The most significant adverse effect (pancytopenia) is not strictly related to drug concentrations in plasma (9); however, other toxic side effects (ataxia, lethargy, hirsutism)
are dose dependent and account for the need to monitor the concentrations in plasma of total CBZ and, when there are concomitant physiopathological dysprotidemias (8, 10, 11), of the free fraction also. In recent years,many analytical methods have been described for monitoring total and free carbamazepine concentrations in plasma (12, 15) . Most are fast, accurate, precise, and simple, but only a few are suitable for use in urgent analyses, assay of small-medium batches of samples, and direct use in outpatient neurology clinics.
A dry-reagent strip test satisfying such requirements has been described (16) and recently introduced for use with the 
Materials and Methods

Seralyzer ARtSCarbamazepine Reagent Strip
Principle. The drug (CBZ) in the sample competes with a drug-conjugate for a limited number of antibody binding sites. The corljugate consists of the drug linked to the glucose oxidase prosthetic group, fiavin adenine dinucleotide (FAD). The unbound FAD-conjugate combines with apoglucose oxidase to regenerate the biologically active holoenzyme. The reactivated glucose oxidase (EC 1.1.3.4) converts glucose into gluconolactone and hydrogen peroxide, which oxidizes, in the presence of peroxidase (EC 1.11.1.7), the indicator 3,3',5,5'-tetramethylbenzidine (TMB). The blue product thus developed is monitored by reflectance photometry; the color change is directly proportional to the concentration of the drug in the sample.
Materials.
We used Seralyzer &ius CBZ reagents in conjunction with the desk-top Seralyzer reflectance photometer supplied by Miles Italians S.p.A., Ames Division, Cavenago Brianza (Milan), Italy. CBZ reagent strips contain in dry form all the components necessary for the test, i.e., FAD-CBZ conjugate, specific antibody, apoglucose oxidase, glu. cose, peroxidase, TMB, buffer, and additives. Low-(3 mgfL) and high-concentration (15 mg/L) calibrators needed for the two-point calibration curve, as well as serum controls (6,9, and 12 mgfL), are solutions of CBZ in human serum. Instructions specific to the test are contained in the preprogrammed CBZ Test Module, which includes an interference ifiter (740 rim) and appropriate mathematical algorithms for calibration-curve storage and calculation of test results.
Procedure. Dispense 30 pL of 1:27.7 diluted sample (30 pL of serum or heparinized plasma plus 800 pL of distilled water) onto the reagent pad of the plastic strip, then insert the strip into the photometer. The Test Module kinetically monitors the rate of the color development and, within 80s, derives the CBZ concentration in the sample from the stored calibration line-prepared previously by processing calibrators similarly-and displays the result directly in clinically useful units. At the recommended sample dilution, the measuring interval ranges from 1.5 to 18 mgIL. Flashing displays of 1.5 and 18 indicate underrange and overrange values, respectively. Samples with a value higher than 18 mg/L can be further diluted threefold and re-analyzed in the dilution mode of the Seralyzer instrument, which then displays the corrected concentration of CBZ. Thus, the measuring range extends up to 54 mgfL, a concentration practically never encountered in biological fluids. The manufacturer does not give instructions for assaying underrange values. We found (see Table 1 ) that concentrations of total CBZ as low as 0.5 mg'L can be determined by re-analyzing a sample at a dilution lower than the indicated one and then multiplying the displayed value by the appropriate correction factor.
Comparative Methods
We also assayed CBZ and free CBZ with (a) a fluorescence polarization immunoassay (FPIA) method, using TDx Re- (24) . We also determined with FIPLC the concentrations of CBZ-E, which are not measurable by the immunochemical methods.
Samples, Calibrators, and Standards
We used blood samples taken from epileptic patients, ages 10 to 62 years, who had been treated with CBZ alone for at least three months. The blood was anticoagulated with heparin and centrifuged. The heparinized plasma was divided into three aliquots and stored at -20 #{176}C until assayed for total CBZ by the three analytical methods mentioned above and for CBZ-E by HPLC.
Samples to be tested for free CBZ were immediately filtered by centrifugation (2000 to 3000 x g) through Micropartition System MPS-1 (Amicon Corp., Danvers, MA) ultrafiltration devices. Ultrafuitrates (about 500 pL for each sample) were divided into aliquots and stored at -20 #{176}C until assayed (25,26).
Calibrators and controls used in free CBZ assays were those for the "Free CBZ" method designed for the TDx analyzer (Abbott Labs.): plasma ultrafiltrates supplemented with pure CBZ. Pure CBZ and CBZ-E used for recovery and cross-reactivity studies, as well as for preparing calibrators for HPLC, were from Spelchem S.p.A., Milan, Italy. Salvents for HPLC were from C. Erba S.p.A., Milan, Italy.
Results
Assay range. The test range for the Seralyzer .ms reagent strip for CBZ is 1.5 to 18 mgIL at the recommended dilution (see above). We also tested samples having known concentrations of CBZ at predilutions of 1:14.3, 1:9.9, 1:7.7, and 1:3.7 (adding 60,90, 120, and 300 ,uL of sample, respectively, to 800 ,uL of distilled water). Results are shown in Table 1 .
Recovery. Analytical recovery was assessed (Table 2) by testing in duplicate aliquots of a drug-free plasma supplemented with various amounts of pure CBZ. Recovery (mean ± SD) was 99.9 ± 2.3% (n = in the test range. Recovery was also good for a drug-supplemented overrange sample assayed by the recommended overrange dilution procedure, and for an underrange sample assayed as Precision. Within-run precision was determined from 20 replicate assays of low and high calibrators, and of a human plasma poo1. Between-run precision was assessed from 15 replicates of each of three serum controls, assayed on 15 days by calibrating the instrument each day. Table 3 shows that repeatibility is good (CVs 4.1%).
Method-comparison.
Ninety-six clinical plasma specimens were assayed for CBZ by Seralyzer .ius reagent strip, Interferences. We examined some endogenous compounds for possible interference with the reagent strip assay. CBZ was added gravimetrically (final concentration 5 mg/L) to a drug-free serum and to five different clinical specimens containing high concentrations of the substances tested for interference; these samples were then assayed in duplicate. We found no interference at the indicated concentrations for total bilirubin (45 mgIL) and uric acid (145 mg/L). CBZ was slightly underestimated (by about 10%) in specimens with high concentrations of cholesterol (4.9 g/L) and triglycerides (3.8 g/L) and in a strongly hemolyzed specimen (hemoglobin, 4g/L).
FPIA, and HPLC, and for CBZ-E by HPLC. Cross reactivity by the metabolite CBZ-E-which often occurs in immunochemical assays-did not affect the reagent strip immunoassay at the concentrations of CBZ-E in the samples (mean CBZ-E
We also explored the effect of the most widely used anticoagulants on test results. Blood from a patient receiv- Cross reactivity. To assess cross reactivity of the metabolite CBZ-E, we added CBZ gravimetrically to seven aliquots of a drug-free plasma to give a concentration of 5 mg/L; we then supplemented these aliquots with as much as 15 mg of CBZ-E per liter and tested the samples in duplicate by both Seralyzer ARI5 reagent strip and FPIA assay. In both immunochemical assays, CBZ-E at 5 mg/L led to marked overestimates (>25%) of CBZ (Table 4) . These increased values correlated well with CBZ-E concentrations: CBZ found = 0.363 CBZ-E -0.547 (r 0.993, n = 6). The method-comparison results also document that CBZ-E <5.0 mgtL does not cross-react significantly.
Calibration stability. Using Seralyzer AIU5 reagent strips from the same bottle, we tested low and high calibrators and a serum control for CBZ at two-to-five-day intervals over a 21-day period, having calibrated the Seralyzer instrument on the first day of the study only. As Table 5 indicates, the calibration curve showed good stability, the CVs being not significantly different from those of the precision study.
Free CBZ assay. We examined the possibility of extending the use of the Seralyzer ARIS reagent strip to measure free CBZ also. For better accuracy in assays with plasma ultraifitrates, we prepared calibrators by supplementing plasma ultrafiltrates with CBZ (1.5 mg/L and 4 mgIL for low and high concentrations).
We then tested for free CBZ 20 plasma ultrafiltrates and compared results with both the "CBZFree" FPIA method and the HPLC technique. Regression plots are shown in Figure 2 . The correlation of the reagent strip test with the other immunochemical method was very good, but results were moderately greater than those by the chromatographic technique.
Discussion
We found the Seralyzer axis reagent strip test for CBZ to be accurate and precise for measuring total CBZ in plasma, the use claimed by the manufacturer,and also for free CBZ in plasma ultrafiltrates. Cross reactivity with CBZ-E, typical of all immunoassays (27) Cross reaction may be a problem if one is testing plasma ultrailltrates, because CBZ-E is less bound to plasma proteins; its free fraction is thus proportionately greater than that of CBZ (28). For plasma, CBZ-E/CBZ ratios were 0.165 (SD 0.05) (n = 96), whereas for plasma ultrafiltrates (n = 20, with CBZ ranging from 0.42 to 5.9 mg/L) CBZ-E/ CBZ ratios were 0.42 (SD 0.11). Comparison with HPLC results (Figure 1) shows in fact a 5-10% overestimate of CBZ, which is nevertheless of slight clinical significance.
We did not notice important interference from some endogenous substances at concentrations at least twice the normal levels or from common anticoagulants at concentrations fourfold the usual ones.
As pointed out by the manufacturer, ambient moisture 
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The different degree of humidity to which they could have 7.4 been exposed might lead to different results: assays we made 7.8 with reagent strips from different bottles and without recall-
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brating the instruments gave CVs of 38%.
The apparent increase in sensitivity we obtained by using samples less prediluted cannot be extended to <0.5 mg/L with plasma samples, because the color development is masked by the highly concentrated matrix of the sample, which causes results to be underestimated by 20%. This effect does not occur when plasma ultrafiltrates are assayed, so concentrations as low as 0.25 mg/L can be measured.
In conclusion, the Seralyzer ius method for the quantitative determination of CBZ provides reliable results over the whole clinically significant range of concentrations. We also appreciated some advantages of this system: simplicity of use, versatility, and rapidity; they make it, perhaps, the fastest system for analyzing small batches of samples and, certainly, the fastest one for urgent analyses. Availability of other reagent strip tests for drug assays and reasonable costs are further positive aspects that make this system valuable for laboratories of clinical pharmacology. Its adoption in various clinical settings should promptly satisfy demands for urgent yet reliable answers, even when skilled operators are not available.
